KYMR insider ownership: who sold, why, and what they still hold

What stands out

Outside holders and shareholders represented on the board, not part of management, sold heavily: Bruce Booth ($220M) and BVF PARTNERS L P/IL ($174M).Bruce Booth: largest sale, Jun 26, 2026 · BVF PARTNERS L P/IL: largest sale, Jun 26, 2026

A share of stake is shown for 0 of the 10 officers and directors who sold. 14 are left out

Left out: Nello Mainolfi, Bruce Jacobs, Jared Gollob, Jeremy Chadwick, Brian Adams, Noah Goodman, Jeffrey Albers, Gorjan Hrustanovic, Bruce Booth, Pamela Esposito, Elena Ridloff, John Maraganore, Victor Sandor and Terence Rooney (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Nello Mainolfi

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$36.8MDisclosed plan

Jeremy Chadwick

Chief Operating Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$15.6M97% planned, 3% to cover taxes

Bruce Jacobs

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$10.0M89% planned, 11% to cover taxes

Jared Gollob

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$8.9M90% planned, 10% to cover taxes

Pamela Esposito

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.1MDisclosed plan

All 10 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Oct 1, 2026Nello Mainolfi sold 30K shares ($3.4M) under a disclosed trading plan. 30K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Nello Mainolfi Chief Executive Officer, Director	30,000	$113.80	n/a	n/a	Oct 1, 2026	Oct 1, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

BVF PARTNERS L P/IL sold $174M and Bruce Booth (for the outside shareholder represented on the board) sold $220M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Kymera Therapeutics, Inc. CEO selling stock?

Yes. Nello Mainolfi sold 380K shares ($36.8M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Kymera Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 96% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 4% were to cover taxes. A trading plan schedules sales in advance.

Are any Kymera Therapeutics, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold10 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Nello Mainolfi Chief Executive Officer, Director	$36.8M 380K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Jeremy Chadwick Chief Operating Officer	$15.6M 194K shares	Not confirmed share of stake is being verified. Why	97% under a disclosed plan, 3% to cover taxes
Bruce Jacobs Chief Financial Officer	$10.0M 90K shares	Not confirmed share of stake is being verified. Why	89% under a disclosed plan, 11% to cover taxes
Jared Gollob Chief Medical Officer	$8.9M 119K shares	Not confirmed share of stake is being verified. Why	90% under a disclosed plan, 10% to cover taxes
Pamela Esposito Director	$3.1M 38K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Noah Goodman Chief Business Officer	$2.2M 23K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Bruce Booth Director	$2.2M 24K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Elena Ridloff Director	$1.3M 15K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Brian Adams Chief Legal Officer	$744K 6.4K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Jeffrey Albers Director	$449K 5K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

Board members representing outside shareholders, reported separately: Bruce Booth (the shareholder sold $220M). Details

Outside holder, reported separately: BAKER BROS. ADVISORS LP (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: BVF PARTNERS L P/IL (an outside shareholder, not part of management). Sold $174M (1.63M shares) from Jun 26, 2026 to Jun 26, 2026. Latest filing

The full ownership picture0 of 14 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Nello Mainolfi

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Nello Mainolfi are complete.

Chief Executive Officer, Director

n/a

−380K

n/a

Vesting, gifts, unvested awards and holding lines for Nello Mainolfi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Nello Mainolfi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
505,559	$2.08	Nov 13, 2029	$57.7M
14,284	$2.08	Nov 13, 2029	$1.6M
288,456	$5.33	May 13, 2030	$32.0M
272,505	$38.53	Feb 29, 2032	$21.1M
446,882	$32.07	Feb 28, 2033	$37.6M
530,000	$43.50	Feb 28, 2034	$38.5M
60,000	$2.08	Nov 13, 2029	$6.8M
365,000	$30.17	Mar 2, 2035	$31.4M
215,000	$90.10	Mar 1, 2036	$5.6M

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Bruce Jacobs

Chief Financial Officer

n/a

−90K

n/a

Vesting, gifts, unvested awards and holding lines for Bruce Jacobs

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bruce Jacobs are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Jared Gollob exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
187,500	$43.50	Feb 28, 2034	$13.6M
60,000	$30.17	Mar 2, 2035	$5.2M
35,300	$90.10	Mar 1, 2036	$919K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Jared Gollob

Chief Medical Officer

n/a

−119K

n/a

Vesting, gifts, unvested awards and holding lines for Jared Gollob

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jared Gollob are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Bruce Jacobs exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
34,083	$5.33	May 13, 2030	$3.8M
146,250	$43.50	Feb 28, 2034	$10.6M
60,000	$30.17	Mar 2, 2035	$5.2M
35,300	$90.10	Mar 1, 2036	$919K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Jeremy Chadwick

Chief Operating Officer

n/a

−194K

n/a

Vesting, gifts, unvested awards and holding lines for Jeremy Chadwick

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeremy Chadwick are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
68,633	$29.64	May 22, 2023	$5.9M
58,263	$43.50	Feb 28, 2034	$4.2M
45,434	$30.17	Mar 2, 2035	$3.9M
25,150	$90.10	Mar 1, 2036	$654K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Brian Adams

Chief Legal Officer

n/a

−6.4K

n/a

Vesting, gifts, unvested awards and holding lines for Brian Adams

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brian Adams are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
105,000	$43.30	Sep 2, 2035	$7.6M
8,250	$90.10	Mar 1, 2036	$215K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Noah Goodman

Chief Business Officer

n/a

−23K

n/a

Vesting, gifts, unvested awards and holding lines for Noah Goodman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Noah Goodman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
90,000	$21.05	Apr 7, 2035	$8.6M
18,450	$90.10	Mar 1, 2036	$480K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Jeffrey Albers

Director

n/a

−5K

n/a

Vesting, gifts, unvested awards and holding lines for Jeffrey Albers

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeffrey Albers are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,000	$14.18	Jun 14, 2032	$714K
16,000	$31.20	Jun 17, 2034	$1.4M
16,000	$46.47	Jun 24, 2035	$1.1M
6,068	$99.87	Jun 23, 2036	$99K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Gorjan Hrustanovic

Director

n/a

Vesting, gifts, unvested awards and holding lines for Gorjan Hrustanovic

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gorjan Hrustanovic are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
16,000	$31.20	Jun 17, 2034	$1.4M
16,000	$46.47	Jun 24, 2035	$1.1M
6,068	$99.87	Jun 23, 2036	$99K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Bruce Booth

Director

n/a

−24K

n/a

Vesting, gifts, unvested awards and holding lines for Bruce Booth

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bruce Booth are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
28,127	$20.00	Aug 19, 2030	$2.7M
16,000	$31.20	Jun 17, 2034	$1.4M
16,000	$46.47	Jun 24, 2035	$1.1M
6,068	$99.87	Jun 23, 2036	$99K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Pamela Esposito

Director

n/a

−38K

n/a

Vesting, gifts, unvested awards and holding lines for Pamela Esposito

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Pamela Esposito are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
24,127	$29.55	Sep 3, 2030	$2.1M
7,000	$14.18	Jun 14, 2032	$714K
9,000	$31.20	Jun 17, 2034	$764K
16,000	$46.47	Jun 24, 2035	$1.1M
6,068	$99.87	Jun 23, 2036	$99K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Elena Ridloff

Director

n/a

−15K

n/a

Vesting, gifts, unvested awards and holding lines for Elena Ridloff

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elena Ridloff are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
4,500	$20.29	Jun 28, 2032	$431K
13,000	$31.20	Jun 17, 2034	$1.1M
16,000	$46.47	Jun 24, 2035	$1.1M
6,068	$99.87	Jun 23, 2036	$99K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

John Maraganore

Director

n/a

Vesting, gifts, unvested awards and holding lines for John Maraganore

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Maraganore are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
16,000	$31.20	Jun 17, 2034	$1.4M
16,000	$46.47	Jun 24, 2035	$1.1M
6,068	$99.87	Jun 23, 2036	$99K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Victor Sandor

Director

n/a

Vesting, gifts, unvested awards and holding lines for Victor Sandor

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Victor Sandor are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
16,000	$31.20	Jun 17, 2034	$1.4M
16,000	$46.47	Jun 24, 2035	$1.1M
6,068	$99.87	Jun 23, 2036	$99K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Terence Rooney

Chief Medical Officer

n/a

Vesting, gifts, unvested awards and holding lines for Terence Rooney

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Terence Rooney are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
76,000	$110.05	Jul 26, 2036	$461K

Estimate: options held × ($116.12 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Holdings and share of stake for Kymera Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$81.2M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $81.2M across 893,873 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $78.0M · 96%

The lighter segment is sales with no plan disclosed in the filing ($3.3M), including tax-related sales outside a plan.

Taxes

$4.1M of sales (5.0%) cite tax obligations in their footnotes, $819K of them also under a plan. Example: Brian Adams, Sep 4, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Nello Mainolfi Chief Executive Officer, Director	380K	$36.8M	100%	45%	Oct 29, 2025 to Oct 1, 2026
Jeremy Chadwick Chief Operating Officer	194K	$15.6M	97%	19%	Mar 2, 2026 to May 27, 2026
Bruce Jacobs Chief Financial Officer	90K	$10.0M	89%	12%	Mar 2, 2026 to Jun 30, 2026
Jared Gollob Chief Medical Officer	119K	$8.9M	90%	11%	Oct 15, 2025 to Mar 4, 2026
Pamela Esposito Director	38K	$3.1M	100%	4%	Dec 17, 2025 to Mar 20, 2026
Noah Goodman Chief Business Officer	23K	$2.2M	100%	3%	Apr 9, 2026 to Jul 1, 2026
Bruce Booth Director	24K	$2.2M	100%	3%	Apr 14, 2026 to Jun 17, 2026
Elena Ridloff Director	15K	$1.3M	100%	2%	Mar 31, 2026 to May 11, 2026
Brian Adams Chief Legal Officer	6.4K	$744K	0%	0.9%	Sep 4, 2026 to Sep 4, 2026
Jeffrey Albers Director	5K	$449K	100%	0.6%	Dec 8, 2025 to Dec 8, 2025

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$5.5M	$5.5M	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$18.3M	$18.3M	$0	$0
Jan 2026	$374K	$374K	$0	$0
Feb 2026	$2.9M	$2.9M	$0	$0
Mar 2026	$15.2M	$12.7M	$2.5M	$0
Apr 2026	$6.8M	$6.8M	$0	$0
May 2026	$1.6M	$1.6M	$0	$0
Jun 2026	$10.7M	$10.7M	$0	$0
Jul 2026	$15.6M	$15.6M	$0	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$744K	$0	$744K	$0
Oct 2026	$3.4M	$3.4M	$0	$0

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 13, 2025	Sold	Held Oct 13, 2026	Still held
Bruce Booth ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Bruce Booth are complete. Director	n/a	−2.09M	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Bruce Booth Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bruce Booth are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 5x the 5-year average. 10 insiders sold; the average is 5 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	894K	10	$81.2M
Oct 13, 2025 1 year earlier	200K	8	$9.5M
Oct 13, 2024 2 years earlier	141K	7	$5.6M
Oct 14, 2023 3 years earlier	3.4K	3	$105K
Oct 14, 2022 4 years earlier	130K	3	$7.4M
Oct 14, 2021 5 years earlier	487K	4	$25.0M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty14 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Kymera Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology296 filings on record, 67 filed in the 12-month period, and how we read them

All 296 Forms 3, 4 and 5 on record for Kymera Therapeutics, Inc. (SEC CIK 1815442), filed from Aug 20, 2020 to Oct 1, 2026; 67 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (13)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Ellen Chiniara	Mar 3, 2025	80,085 shares, last reported balance as of Mar 3, 2025
Leigh Morgan	Jun 20, 2024	No balance on record
Joanna Horobin	Jun 7, 2024	No balance on record
Atlas Venture Fund X, L.P.	Mar 13, 2024	11,267,917 shares, last reported balance as of Mar 13, 2024
Elaine Caughey	Mar 3, 2023	18,986 shares, last reported balance as of Mar 2, 2023
Donald Nicholson	Jun 16, 2022	25,255 shares, last reported balance as of Aug 20, 2020
Richard Chesworth	Aug 27, 2021	No balance on record
Steven Hall	Jun 17, 2021	No balance on record
Steven Hall	Jun 17, 2021	2,192,249 shares, last reported balance as of Aug 25, 2020
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	Aug 27, 2020	959,211 shares, last reported balance as of Aug 25, 2020
Alexandria Venture Investments, LLC	Aug 25, 2020	467,932 shares, last reported balance as of Aug 25, 2020
Redmile Group, LLC	Aug 25, 2020	1,630,660 shares, last reported balance as of Aug 25, 2020
Andrew Hedin	Aug 21, 2020	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Kymera Therapeutics, Inc. insiders sold $81.2M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Kymera Therapeutics, Inc. CEO selling stock?

Why are Kymera Therapeutics, Inc. insiders selling?

Are any Kymera Therapeutics, Inc. insiders buying?

The evidence

Taxes

Sales by month